Effect of DA-5515 (Circulan® Soft Cap.) in Patients With Chronic Fatigue Symptoms Due to Impaired Blood Circulation

A Placebo-controlled, Randomized, Double-blind, Parallel, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of DA-5515 (Circulan® Soft Cap.) in Patients With Chronic Fatigue Symptoms Due to Impaired Blood Circulation

The aim of the present clinical study is to evaluate the efficacy and safety of the DA-5515 (Circulan Soft Cap.) in patients with chronic fatigue symptoms due to impaired blood circulation.

This study is conducting to assess the efficacy and safety of the DA-5515 (Circulan Soft Cap.), which has been known to have a fatigue recovery effect due to impaired blood circulation.

Inclusion Criteria:

• Rutherford's category 0/0 or Ⅰ/1
• ABI <1.0
• CIS greater than 76
• HADS less than or equal to 10
• Subjects who have fatigue symptoms more than 1 month

Exclusion Criteria:

• Subjects who have diseases that can cause fatigue
• Subjects who are taking medication that can cause fatigue